Abstract: The subject matter of this specification can be embodied in, among other things, a method that includes receiving cluster information comprising categories and total numbers of media receivers (e.g. television (TV) viewers) associated with the categories and receiving sample data comprising numbers of advertisements (ads) displayed to sampled receivers (e.g., TV viewers) that are classified within the categories. The method also includes calculating probabilities for numbers of ads displayed to the total numbers of receivers associated with the categories, wherein the calculation is based on the cluster information and the sample data, merging the calculated probabilities associated with two or more of the categories, and outputting an estimated number of ads displayed based on the merged probabilities.

Abstract: Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.

Abstract: Methods, systems and apparatus, including computer program products, provide adjustments to advertisement impression estimates based on sampled data. According to one method, an estimated number of advertisement impressions is made based on the sampled data and the estimate is discounted to achieve a level of certainty that the resulting discounted estimate is less than the actual number of advertisement impressions. The amount of the discount can be determined based on a sampling error model of the sampling data.

Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders.

Abstract: A universal linker for solid-phase nucleic acid synthesis that is cleaved under conditions orthogonal to those used during the synthesis and deprotection of nucleic acids such as dsDNA or RNA fragments is disclosed. The invention includes compounds of the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of OH, OR.sub.2 and an amino functionalized support and n is an integer ranging from about 1 to about 1000 or more preferably from about 1 to about 100 or greater and R.sub.2 is an alkyl (C.sub.1-20) or greater.